|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01/09/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 01/01/2023 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 59 | 26/09/2017 | |
Bruno Schick
BRD | Director/Board Member | - | 26/09/2017 |
Günter von Au
CHM | Chairman | 75 | 27/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| +1.33% | -2.26% | +16.81% | +67.05% | 46.96B | ||
| +0.12% | -1.59% | +47.86% | +123.16% | 39.63B | ||
| -0.64% | -2.80% | -8.19% | +15.25% | 12.07B | ||
| -0.99% | -8.34% | +11.63% | +69.12% | 11.61B | ||
| +0.58% | 0.00% | +30.65% | +147.62% | 9.11B | ||
| +0.39% | -0.38% | +20.86% | +40.63% | 7.47B | ||
| +0.80% | +1.82% | +43.27% | -11.49% | 7.18B | ||
| -2.54% | -1.90% | +15.45% | +189.85% | 6.79B | ||
| -0.97% | -2.30% | -30.37% | +24.93% | 5.75B | ||
| Average | -0.19% | -1.82% | +16.44% | +74.01% | 15.23B | |
| Weighted average by Cap. | +0.26% | -2.86% | +23.19% | +81.97% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















